Same-day Strattera appointment in Florida

If you’ve been wondering whether you can access ADHD non-stimulant medication through telehealth, you’re not alone. Thousands of adults and families are exploring online mental health care as a practical, accessible way to manage ADHD symptoms—especially when in-person appointments are hard to schedule or simply don’t fit into busy lives.

The short answer: Yes, you can get ADHD non-stimulant medication via telehealth in most cases. In this comprehensive guide, we’ll walk you through exactly how it works, what the federal and state rules say, who can prescribe these medications online, and what you need to know to get started safely and legally.

Understanding ADHD Non-Stimulant Medications

Before diving into the telehealth aspect, let’s clarify what we mean by ‘ADHD non-stimulant medication.’

What Are Non-Stimulant ADHD Medications?

Non-stimulant medications are prescription drugs approved by the FDA to treat ADHD that don’t contain stimulant compounds like amphetamine or methylphenidate. The most common non-stimulant ADHD medication is Strattera (atomoxetine), but others include guanfacine (Intuniv) and clonidine (Kapvay).

Strattera (atomoxetine) is particularly important in the telehealth conversation because it’s not a controlled substance. This distinction matters enormously for telehealth prescribing. Unlike stimulant medications such as Adderall or Ritalin (which are Schedule II controlled substances under the DEA), Strattera carries no federal restrictions related to online prescribing or telehealth consultations.

How Strattera Works

Strattera works differently than stimulants. It’s a selective norepinephrine reuptake inhibitor (SNRI) that gradually increases levels of norepinephrine in the brain, helping improve attention, reduce impulsivity, and manage hyperactivity. Unlike stimulants that work within hours, Strattera typically takes 4-6 weeks to reach full effectiveness.

Key Benefits of Non-Stimulant Medications

• No abuse potential: Strattera isn’t habit-forming and has no potential for dependency
• Longer-lasting: Provides 24-hour coverage with a single daily dose
• Easier prescribing: Can be prescribed with refills (unlike Schedule II stimulants which require new prescriptions monthly)
• May be better tolerated: Some patients who experience anxiety or sleep issues with stimulants do better on non-stimulants
• Insurance-friendly: Often easier to get approved, with 90-day supplies commonly available

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Telehealth Rules for ADHD Medications: Where Things Stand in 2025

Understanding the current legal landscape is crucial if you’re considering telehealth for ADHD treatment.

The Ryan Haight Act and Its Exceptions

Normally, the Ryan Haight Act (passed in 2008) requires an in-person medical evaluation before a doctor can prescribe controlled substances online. This federal law was designed to prevent illegal online pharmacies from selling controlled medications without proper medical oversight.

However—and this is critical—the Ryan Haight Act only applies to controlled substances. Since Strattera and other non-stimulant ADHD medications are not controlled substances, they were never subject to this in-person requirement. This means that even before COVID-19, providers could legally prescribe Strattera via telehealth.

COVID-Era Telehealth Flexibilities (Still Active Through 2025)

During the COVID-19 public health emergency, the DEA issued temporary rules allowing healthcare providers to prescribe controlled substances (including stimulant ADHD medications like Adderall) via telehealth without a prior in-person exam. This was a game-changer for ADHD care.

Current status as of December 2025: The DEA finalized its ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities’ in November 2024, extending telehealth prescribing rules for Schedule II-V controlled substances through December 31, 2025.

What this means for you:

• Providers can still prescribe stimulant ADHD medications via telehealth through the end of 2025
• Non-stimulants like Strattera remain prescribable via telehealth with no special restrictions (as they always were)
• A fourth extension for 2026 is currently under review by the Office of Management and Budget

What Happens After December 31, 2025?

This is the million-dollar question. The DEA has proposed a ‘Special Registration’ system that would create permanent telehealth pathways for controlled substance prescribing with additional safeguards, but no final rule has been published yet.

For patients seeking non-stimulant medications, this uncertainty doesn’t matter. Since Strattera and similar medications aren’t controlled substances, they can continue to be prescribed via telehealth regardless of what happens with DEA controlled substance rules.

If you’re currently on or considering stimulant medications via telehealth, however, stay in close contact with your provider about contingency plans if the rules change in 2026.

State-by-State Telehealth Rules: What You Need to Know

While federal law sets the baseline, state laws add another layer of rules that telehealth providers must follow. Your provider must be licensed in your state and follow that state’s specific telehealth regulations.

The good news: No state completely bans telehealth for ADHD treatment. However, some states have implemented additional requirements, especially for controlled substances.

States with Minimal Restrictions (Most Telehealth-Friendly)

California, Illinois, and Pennsylvania have embraced telehealth with minimal barriers. In these states:

• No mandatory in-person exams for non-controlled medications
• Telehealth visits can establish a valid provider-patient relationship
• Prescriptions can be written and electronically sent to your pharmacy after a video consultation

New Hampshire recently updated its laws (effective August 2025) to remove prior in-person requirements for controlled substance prescribing via telehealth, requiring only an annual follow-up evaluation. For non-controlled medications like Strattera, there are no special requirements beyond standard medical practice.

States with Moderate Requirements

Texas is generally telehealth-friendly, especially for mental health care. Texas allows telemedicine for ADHD treatment without requiring an in-person visit. However, Texas does have some restrictions on who can prescribe certain medications (more on that below in the provider section).

Florida has specific rules worth noting. Florida law generally prohibits telehealth prescribing of Schedule II controlled substances (like stimulants) unless the medication is prescribed for a psychiatric condition. Since ADHD is a psychiatric disorder, stimulant prescriptions via telehealth are allowed under this exception. For Strattera, there are no special restrictions—it can be prescribed via telehealth just like any other non-controlled medication.

Florida does require prescription monitoring program (PMP) checks before every controlled substance prescription, though this doesn’t apply to Strattera.

States with Stricter Telehealth Requirements

New York reinstated an in-person evaluation requirement in 2025 for prescribing any controlled substance via telemedicine. This means if you’re in New York and want stimulant medication, you’ll need an initial in-person exam. However, this rule doesn’t affect non-controlled medications—New York providers can prescribe Strattera via telehealth without requiring an in-person visit.

Alabama has perhaps the strictest telehealth rules in the nation. Alabama requires an in-person visit within 12 months if you’re receiving ongoing telehealth treatment, and for initial controlled substance prescribing, requires either a prior in-person exam or having a nurse or other licensed medical professional physically present with you during the telehealth visit.

The silver lining: Alabama’s 12-month in-person requirement is waived for mental health services. Since ADHD is a mental health condition, psychiatric telehealth for ADHD may fall under this exception. Additionally, these strict rules primarily target controlled substances, so Strattera prescribing via telehealth faces fewer barriers.

The Bottom Line on State Rules

For patients seeking non-stimulant ADHD medication via telehealth, state restrictions are generally minimal. The strictest state rules focus on controlled substances, which Strattera is not. As long as your provider is licensed in your state and follows standard medical practice, you should be able to access non-stimulant ADHD treatment remotely.

Who Can Prescribe ADHD Medication via Telehealth?

Not all healthcare providers have the same prescribing authority, and this varies significantly by state.

Physicians (MD/DO)

All states allow licensed physicians to prescribe ADHD medications—both stimulants and non-stimulants—via telehealth, assuming they follow federal DEA rules and state regulations. If your telehealth provider is a psychiatrist or primary care physician, they have full prescribing authority.

Nurse Practitioners (NPs)

Nurse practitioner authority varies dramatically by state:

Full Practice Authority States (Independent NPs):States like California, New York, New Hampshire, and Illinois allow nurse practitioners to practice independently and prescribe controlled substances (including Schedule II stimulants) after meeting certain experience requirements. In these states, an NP can evaluate you via telehealth and prescribe Strattera or stimulant medications without needing a physician’s approval.

Collaborative Practice States:In states like Florida, Pennsylvania, and Texas, NPs must work under a collaborative agreement with a physician. This doesn’t mean the physician needs to be present during your telehealth visit, but there must be an established supervisory relationship.

Restricted States:Some states impose significant limitations:

• Texas: NPs cannot prescribe Schedule II medications (like stimulant ADHD drugs) in regular outpatient settings—only in hospitals or hospice care. However, Texas NPs can prescribe Strattera and other non-controlled ADHD medications.
• Georgia: NPs cannot prescribe Schedule II controlled substances at all, even with physician collaboration. For stimulant medications in Georgia, you’d need to see a physician. Non-stimulants like Strattera are fine for NP prescribing under collaboration.
• Alabama: NPs can prescribe Schedule II-V medications if they obtain special credentials (QACSC certificate and LPSP permit) and work under physician collaboration, but many have restricted formularies in practice.

Physician Assistants (PAs)

Physician assistants generally practice under physician supervision in all states. Their controlled substance prescribing authority often mirrors that of NPs in their state, though typically with slightly more restrictions. PAs can prescribe non-controlled medications like Strattera in all states under appropriate supervision.

Why This Matters for Your Care

When you connect with a telehealth platform, they should match you with a provider who has appropriate authority in your state. Reputable platforms like Klarity Health ensure their clinicians are properly licensed and credentialed to prescribe ADHD medications in your specific state.

If you’re considering stimulant medications and live in a state with NP/PA restrictions, you may specifically need to request a physician appointment. For non-stimulant medications, you’ll have more flexibility in provider type.

How Telehealth ADHD Evaluation and Treatment Works

Understanding what to expect can help you prepare for a successful telehealth ADHD consultation.

The Initial Evaluation Process

A legitimate telehealth ADHD evaluation is comprehensive and follows the same diagnostic criteria used in traditional in-person visits. Here’s what you can typically expect:

1. Comprehensive Intake QuestionnaireBefore your video visit, you’ll complete detailed questionnaires about:

• Current ADHD symptoms and their impact on work, school, and relationships
• Childhood symptoms and onset (ADHD is a lifelong condition that begins in childhood)
• Medical history, including any heart conditions, high blood pressure, or mental health issues
• Current medications and any history of substance use
• Family history of ADHD or other psychiatric conditions

2. Video Consultation with a Licensed ProviderYour provider will conduct a clinical interview that typically lasts 30-60 minutes. They’ll:

• Review your questionnaire responses in detail
• Ask about symptoms in multiple settings (work, home, social situations)
• Assess for other conditions that might mimic or co-occur with ADHD (like anxiety, depression, or bipolar disorder)
• Discuss your treatment goals and preferences
• Explain treatment options, including both medication and non-medication approaches

3. Diagnostic AssessmentThe provider will use DSM-5 criteria for ADHD diagnosis. This requires:

• Evidence of symptoms before age 12
• Symptoms present in two or more settings
• Clear evidence that symptoms interfere with functioning
• Symptoms not better explained by another condition

Some providers use standardized rating scales like the Adult ADHD Self-Report Scale (ASRS) or request collateral information from family members to confirm symptoms.

4. Treatment Plan DevelopmentIf ADHD is diagnosed, your provider will discuss treatment options. For non-stimulant medications:

• Strattera is often recommended for patients who can’t take stimulants, have anxiety concerns, or prefer a non-controlled medication
• Your provider will explain that Strattera takes 4-6 weeks to reach full effectiveness
• They’ll discuss potential side effects (decreased appetite, nausea, mood changes, rare but serious risk of liver problems or suicidal thoughts in youth)
• They’ll set expectations for follow-up appointments

What Happens After Your Initial Visit

Prescription and Pharmacy:If medication is prescribed, your provider will electronically send the prescription to your pharmacy of choice. For Strattera:

• Prescriptions can include refills (unlike stimulants)
• 90-day supplies are often available
• Most insurance plans cover Strattera, though prior authorization may be required
• Generic atomoxetine is available and much less expensive than brand-name Strattera

Follow-Up Schedule:Reputable providers will schedule follow-up visits:

• Initial check-in at 2-4 weeks to assess side effects and early response
• Another follow-up at 6-8 weeks to evaluate full therapeutic effect
• Ongoing visits every 1-3 months depending on your stability and needs

During follow-ups, your provider will:

• Assess symptom improvement using rating scales
• Check for side effects
• Monitor blood pressure and heart rate (often self-reported for telehealth)
• Adjust dosage if needed
• Screen for any misuse concerns or emerging issues

Documentation You May Need

To strengthen your evaluation, consider gathering:

• Previous ADHD evaluations or diagnoses (if available)
• Report cards or performance reviews showing longstanding attention issues
• Letters from family members who knew you in childhood
• Current medication lists
• Records of any prior ADHD medication trials

Safety Considerations and Patient Eligibility

Telehealth ADHD treatment isn’t appropriate for everyone. Responsible providers screen carefully.

You May NOT Be Eligible for Stimulant Medications via Telehealth If:

• You have uncontrolled high blood pressure or serious heart disease
• You have a history of substance use disorder or current concerns about medication misuse
• You have unstable bipolar disorder, psychosis, or severe mental health issues requiring in-person psychiatric care
• You’re seeking early refills, higher-than-standard doses, or showing other red flags for potential misuse
• You’re unable or unwilling to participate in ongoing monitoring

For non-stimulant medications like Strattera, eligibility is generally broader, but you still need a thorough evaluation and legitimate ADHD diagnosis.

Contraindications Specific to Strattera

Your provider will screen for conditions that make Strattera unsafe:

• Narrow-angle glaucoma (an absolute contraindication)
• Recent MAOI use (within past 14 days—dangerous interaction)
• Severe liver disease (Strattera is metabolized by the liver)
• Severe cardiovascular disease (Strattera can increase blood pressure and heart rate)
• Pregnancy (especially first trimester—benefits must clearly outweigh risks)

Age Considerations

Most telehealth ADHD platforms focus on adults (18+) or older teens. For children under 12-13, in-person evaluation is generally preferred because:

• Physical examination may be more important in ruling out other conditions
• Developmental assessment is more complex
• Many states have stricter rules about prescribing controlled substances to minors via telehealth

If you’re seeking care for a child, ask specifically whether the platform treats pediatric patients and what their age cutoffs are.

The Importance of Honest Communication

The quality and safety of your telehealth ADHD care depends on the information you provide. Because your provider can’t physically examine you, they rely heavily on your history and self-reporting.

Be completely honest about:

• Any history of substance use, even if it was years ago
• All current medications, including supplements and over-the-counter drugs
• Mental health history, including depression, anxiety, or mood disorders
• Your motivation for seeking treatment and any pressure from family, school, or work
• Any past experiences with ADHD medications

Remember: your provider is there to help, not judge. They need the complete picture to provide safe, effective care.

The Current Regulatory Landscape and What’s Changing

The ADHD telehealth space has undergone significant scrutiny and evolution.

High-Profile Controversies

In 2022-2023, the DEA and Department of Justice launched investigations into several high-volume telehealth companies, including Cerebral and Done, over concerns about potential over-prescribing of controlled substances without adequate evaluation.

These investigations led to:

• Cerebral announcing it would stop prescribing most controlled substances
• Heightened scrutiny of all telehealth ADHD prescribing practices
• Increased regulatory oversight and enforcement
• Media coverage raising public awareness about potential ‘pill mill’ operations

How Legitimate Providers Responded

Responsible telehealth platforms tightened their practices significantly:

Enhanced evaluation protocols:

• Longer initial consultations (30-60 minutes instead of 15)
• More comprehensive documentation requirements
• Standardized diagnostic tools and rating scales
• Collateral information from family members when possible

Improved safety measures:

• Mandatory prescription drug monitoring program (PDMP) checks
• Periodic urine drug screens for some patients on stimulants
• Treatment agreements outlining expectations and responsibilities
• Clear policies against early refills or dose escalation without clinical justification
• Coordination with primary care providers

Better patient education:

• Detailed information about medication risks and benefits
• Discussion of non-medication treatments (therapy, coaching, lifestyle changes)
• Realistic expectations about medication effects
• Red flags for misuse or diversion

What This Means for Patients in 2025

If you’re seeking legitimate ADHD care via telehealth in 2025, expect a thorough, professional evaluation process similar to what you’d experience in person. This is actually good news—it means you’re getting quality care and that the platform is operating responsibly.

Warning signs of problematic telehealth services:

• Guarantees of getting medication before any evaluation
• Very short consultations (under 15 minutes)
• No discussion of risks, alternatives, or non-medication options
• Unwillingness to communicate with your other healthcare providers
• Offering to ship medications from overseas or from ‘affiliated pharmacies’
• No requirement for follow-up appointments
• Accepting cash only and avoiding insurance

If you encounter these red flags, look elsewhere. Legitimate providers like Klarity Health maintain high clinical standards, accept both insurance and cash payment, and provide transparent pricing—because patient safety and quality care come first.

How Klarity Health Approaches ADHD Telehealth Care

When you choose a telehealth platform for ADHD treatment, you want assurance that you’re getting safe, effective, evidence-based care.

Klarity Health offers several advantages:

Provider Availability:Klarity maintains a network of licensed psychiatrists and psychiatric nurse practitioners across multiple states. This means you can often get an appointment within days rather than waiting months for traditional in-person psychiatric care.

Transparent Pricing:Whether you’re using insurance or paying out-of-pocket, Klarity provides clear upfront pricing. No surprise bills. You’ll know exactly what your visit will cost before you book.

Insurance and Cash Pay Options:Klarity accepts many major insurance plans, making ADHD treatment more affordable. If you don’t have insurance or prefer not to use it, cash pay options are available at competitive rates.

Licensed, Experienced Providers:All Klarity providers are licensed in the states where they practice and have experience in ADHD diagnosis and treatment. They follow evidence-based guidelines and best practices.

Comprehensive Approach:Klarity providers don’t just prescribe medication. They take time to:

• Conduct thorough diagnostic evaluations
• Discuss both medication and non-medication treatment options
• Provide education about ADHD and its management
• Schedule appropriate follow-up care
• Coordinate with your other healthcare providers when helpful

Ongoing Support:Treatment doesn’t end with a prescription. Klarity provides continued access to your provider for follow-ups, dose adjustments, and addressing any concerns that arise during treatment.

Practical Steps to Get Started with Telehealth ADHD Treatment

Ready to explore whether telehealth ADHD treatment is right for you? Here’s how to move forward:

Step 1: Gather Your Information

Before your first appointment:

• Write down your ADHD symptoms and how they affect your daily life
• Note when symptoms first started (remember, ADHD begins in childhood)
• List any previous ADHD evaluations or treatments
• Compile your complete medical history, including medications and conditions
• Identify your pharmacy of choice

Step 2: Choose a Reputable Platform

Look for platforms that:

• Use licensed providers in your state
• Require video consultations (not just questionnaires)
• Have transparent pricing and policies
• Accept your insurance (if you plan to use it)
• Have positive reviews from actual patients
• Offer comprehensive care, not just prescriptions

Step 3: Schedule Your Evaluation

Most platforms let you book online. You’ll:

• Complete intake forms and questionnaires
• Select an appointment time that works for you
• Receive confirmation and instructions for your video visit
• Often get an appointment within a week or two

Step 4: Prepare for Your Video Consultation

For the best experience:

• Test your technology beforehand (camera, microphone, internet connection)
• Find a private space where you can talk openly without interruptions
• Have your information handy (medication lists, symptom notes, pharmacy info)
• Be ready to engage for 30-60 minutes
• Write down questions you want to ask

Step 5: Follow Your Treatment Plan

If medication is prescribed:

• Pick up your prescription promptly
• Take it exactly as directed
• Track your symptoms and any side effects
• Don’t skip or change doses without consulting your provider
• Attend all follow-up appointments
• Communicate openly about what’s working and what isn’t

Step 6: Integrate Other Supports

Medication is often most effective when combined with other approaches:

• Therapy: Cognitive-behavioral therapy (CBT) specifically designed for ADHD can teach coping strategies
• Coaching: ADHD coaches help with organization, time management, and accountability
• Lifestyle changes: Regular exercise, adequate sleep, and stress management improve ADHD symptoms
• Accommodations: Work with school or employer to get appropriate accommodations
• Support groups: Connect with others who understand the ADHD experience

Frequently Asked Questions

Q: Is telehealth ADHD treatment as effective as in-person care?

Research suggests that telehealth psychiatric care—when done properly with video consultations and qualified providers—produces outcomes equivalent to in-person treatment. The key is comprehensive evaluation, proper diagnosis, and ongoing monitoring.

Q: Will my insurance cover telehealth ADHD treatment?

Most insurance plans now cover telehealth mental health services at the same rate as in-person visits, thanks to COVID-era policy changes that have largely been made permanent. Check with your specific plan, and platforms like Klarity can help verify your coverage before you book.

Q: How long does it take for Strattera to work?

Unlike stimulant medications that work within hours, Strattera typically takes 4-6 weeks to reach full therapeutic effect. Some people notice improvements in 1-2 weeks, but full benefits emerge gradually. This requires patience, but also means you don’t need to worry about ‘wearing off’ during the day.

Q: Can I switch from a stimulant to Strattera (or vice versa) via telehealth?

Yes. Many people try both stimulant and non-stimulant ADHD medications before finding what works best. Your telehealth provider can help you transition between medications safely, with appropriate tapering and monitoring.

Q: What if I move to a different state?

Healthcare providers must be licensed in the state where the patient is located during the telehealth visit. If you move, you’ll likely need to establish care with a provider licensed in your new state. Many telehealth platforms operate in multiple states and can help facilitate this transition.

Q: Are there any ADHD medications that absolutely cannot be prescribed via telehealth?

Under current federal rules (through December 2025), all FDA-approved ADHD medications—both stimulants and non-stimulants—can be prescribed via telehealth by qualified providers. However, some state laws may add restrictions, particularly for controlled substances. Your telehealth provider will know what’s permitted in your state.

Q: What happens if the DEA rules change in 2026?

If federal telehealth flexibilities for controlled substances aren’t extended beyond December 31, 2025, patients on stimulant medications might need an in-person evaluation. However, non-stimulant medications like Strattera would be completely unaffected since they were never subject to the Ryan Haight Act’s in-person requirement. Responsible telehealth platforms will communicate any changes well in advance and help patients transition smoothly.

The Bottom Line: Telehealth ADHD Treatment Is Accessible, Safe, and Effective—When Done Right

Telehealth has revolutionized access to ADHD care, making it possible for busy adults, rural patients, and those facing long wait times to get help managing their symptoms. For non-stimulant medications like Strattera, the regulatory landscape is straightforward: they can be prescribed via telehealth in all 50 states without special restrictions or in-person requirements.

Even for stimulant medications, current federal rules (through at least the end of 2025) allow telehealth prescribing, though some states have added their own requirements. The key is choosing a reputable platform that prioritizes patient safety, conducts thorough evaluations, and provides ongoing care.

ADHD is a real medical condition that deserves proper treatment. Whether you’ve lived with undiagnosed ADHD for years or you’re seeking a new approach to managing your symptoms, telehealth can connect you with qualified providers who can help.

The process should be thorough, professional, and focused on your individual needs—not a quick prescription factory. With proper evaluation and ongoing monitoring, telehealth ADHD treatment can be just as effective as traditional in-person care, with the added benefits of convenience and accessibility.

Ready to Take the Next Step?

If you’re considering ADHD treatment via telehealth, Klarity Health makes it simple to connect with licensed providers who can conduct comprehensive evaluations and, if appropriate, prescribe both stimulant and non-stimulant ADHD medications.

With transparent pricing, flexible insurance and cash pay options, and a network of experienced psychiatrists and psychiatric nurse practitioners, Klarity offers accessible, high-quality ADHD care when and where you need it.

Don’t let untreated ADHD symptoms continue to impact your work, relationships, and quality of life. Schedule a consultation today to explore your treatment options and take the first step toward better focus, organization, and functioning.

Citations and Sources

1. DEA ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities’ – Federal Register via FierceHealthcare (November 2024). Confirms DEA extension of telehealth prescribing rules for Schedule II-V controlled substances through December 31, 2025.

2. Sheppard Mullin Healthcare Law Blog – ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions’ via National Law Review (August 15, 2025). Comprehensive 50-state survey of telehealth laws including state-specific requirements for New York, New Hampshire, Texas, Florida, and Alabama.

3. RxAgent Compliance Blog – ‘The Telehealth Compliance Trap: What You Need to Know’ via RxAgent.co (October 2025). Analysis of state telehealth compliance requirements including Alabama’s strict rules and New York’s in-person requirements for controlled substances.

4. Medical News Today – ‘Is Strattera a Controlled Substance?’ via MedicalNewsToday.com (January 14, 2025). Medically reviewed article confirming that Strattera (atomoxetine) is not a DEA-controlled substance.

5. McDermott Will & Emery Legal Update – ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026’ via MWE.com (2025). Details on pending fourth extension of DEA telehealth flexibilities under OMB review.

This article is for informational purposes only and does not constitute medical advice. ADHD diagnosis and treatment should always be provided by qualified, licensed healthcare professionals. Regulations and laws cited are current as of December 17, 2025, and may change. Always verify current requirements with your healthcare provider and consult your state’s medical board for the most up-to-date telehealth regulations.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment